511 related articles for article (PubMed ID: 22922403)
1. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
2. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
3. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
4. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.
Makovey I; Davis T; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2011 Nov; 30(8):1538-40. PubMed ID: 21826718
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
7. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder.
Juszczak K; Adamczyk P; Maciukiewicz P; Drewa T
Pharmacol Rep; 2018 Dec; 70(6):1133-1138. PubMed ID: 30317128
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
11. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
12. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
[TBL] [Abstract][Full Text] [Related]
13. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.
Hegele A; Frohme C; Varga Z; Olbert P; Kranz J; Hofmann R
Urol Int; 2011; 87(4):439-44. PubMed ID: 22004911
[TBL] [Abstract][Full Text] [Related]
14. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
15. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
[TBL] [Abstract][Full Text] [Related]
17. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity.
Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1497-502. PubMed ID: 21717501
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
[TBL] [Abstract][Full Text] [Related]
19. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.
Okamura K; Nojiri Y; Ameda K; Namima T; Suzuki M; Inoue K; Ogawa T; Gotoh M; Homma Y
Int J Urol; 2011 Jun; 18(6):483-7. PubMed ID: 21488978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
